| Literature DB >> 6150277 |
R C Coombes, P Goss, M Dowsett, J C Gazet, A Brodie.
Abstract
4-hydroxyandrostenedione, a potent inhibitor of the aromatase (oestrogen synthetase) system, was given to 11 patients with metastatic breast cancer. After a single 500 mg intramuscular injection a sustained reduction of serum oestradiol was observed for at least 1 week in all patients in whom the steroid was measured. 4 patients responded to treatment for periods of up to 4 months, and healing of bone metastases and reduction in size of soft-tissue metastases was evident. The only side-effects were pain at the injection site and hot flushes. 4-hydroxyandrostenedione is a new and specific aromatase inhibitor which shows promise in the treatment of patients with metastatic breast cancer.Entities:
Mesh：
Substances：
Year: 1984 PMID： 6150277 DOI： 10.1016/s0140-6736(84)92795-8
Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321